Sung-Yu Chu

Dr. Sung-Yu Chu

Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Tsu-Man ChiuTsu-Man Chiu
Tsu-Man Chiu
SCSung-Yu Chu
Sung-Yu Chu
At present, iodinated contrast media (ICM) are mostly non-ionic, have low osmolality, and are safe. Even if adverse drug reactions (ADRs) occur, most are chemo-toxic symptoms and require only observation or H1 antihistamines. However, rare, unpredictable, and even life-threatening hypersensitivity can still occur. The aim of this review is to summarize the issues that all relevant staff need to know about and be able to respond to. The most significant risk factor for ICM hypersensitivity is a history of ICM hypersensitivity. For high-risk populations, we must cautiously weigh the advantages and disadvantages of premedication and be aware that breakthrough reactions may still occur. The best policy for patients with a history of severe ICM hypersensitivity is to avoid the same ICM. If ICM are inevitable, skin tests, in vitro tests, and drug provocation tests may help to find a feasible alternative that is safer. The severity of the hypersensitivity is correlated with the positivity rate of these tests, so there is no need for further investigations for patients with only mild reactions. We should also keep in mind that even excipients in ICM may induce hypersensitivity. Detailed, standardized documentation is essential for correct diagnosis and the prevention of future occurrence.

11 August 2010 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
CHChing-Hsi Hsiao
Ching-Hsi Hsiao
ACAN NING CHAO
AN NING CHAO
SCSung-Yu Chu
Sung-Yu Chu
KLK.-K. Lin
K.-K. Lin
LYL. Yeung
L. Yeung
JLJ.-L. Lin
J.-L. Lin
Conjunctival and corneal calcification (CCC) is the most common form of metastatic calcification in patients with chronic renal failure. The aim of this study is to investigate if severity of CCC correlates with vascular calcification and mortality in maintenance haemodialysis (MHD) patients. One hundred and nine MHD patients were recruited. CCC was evaluated by external eye photographs, and was graded and scored according to modified Porter and Crombie classification system described by Tokuyama et al. Chest X-ray examination was used to evaluate aortic arch calcification. Geographic, haematological, biochemical and dialysis-related data were obtained. The patients were analysed for traditional and non-traditional risk factors for cardiovascular disease stratified by severity of CCC. All patients were followed up for 1 year to investigate the risks for mortality. Forty-three, 35 and 31 patients had mild (scores ≤ 4), moderate and severe (scores ≥ 9) CCC at baseline, respectively. With trend estimation, patients with severe CCC had a significantly higher percentage of severe aortic arch calcification. Multiple linear regression analysis showed that hypertension, haemodialysis duration and corrected calcium level were associated with scores of CCC in MHD patients. Moreover, age, corrected calcium-phosphate level, and moderate and severe CCC were associated with grades of aortic arch calcification. At 1-year follow-up, 11 of 109 (10.1%) patients had died. Multivariate Cox proportional hazards model showed that age, corrected calcium and severe CCC were significant risk factors for all-cause 1-year mortality in MHD patients. Each increment of one score of CCC is associated with a 26.4% increased risk for all-cause mortality. Severity of CCC, which is easily obtained at bedside, acts as an independent predictor for all-cause 1-year mortality in MHD patients.

1 April 2017 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
SLShen-Yen Lin
Shen-Yen Lin
SLSin-Yi Lyu
Sin-Yi Lyu
TSTa-Wei Su
Ta-Wei Su
SCSung-Yu Chu
Sung-Yu Chu
CCChien-Ming Chen
Chien-Ming Chen
PKPo-Jen Ko
Po-Jen Ko

1 January 2020 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Closed access
PDF file
YLYa-Lun Lee
Ya-Lun Lee
YHYen-Ling Huang
Yen-Ling Huang
SCSung-Yu Chu
Sung-Yu Chu
WCWen-Hui Chan
Wen-Hui Chan
MCMing-Huei Cheng
Ming-Huei Cheng
Po-Hsiang TsuiPo-Hsiang Tsui
Po-Hsiang Tsui
Background: Lymphedema is a disease in which tissue swelling is caused by interstitial fluid retention in subcutaneous tissue. It is caused by a compromised lymphatic system. Lymphoscintigraphy is the current and primary modality used to assess lymphatic system dysfunction. Ultrasound elastography is a complementary tool used for evaluating the tissue stiffness of the lymphedematous limb. Tissue stiffness implies the existence of changes in tissue microstructures. However, ultrasound features related to tissue microstructures are neglected in clinical assessments of lymphedematous limbs. In this study, we aimed to evaluate the lymphedematous diagnostic values of ultrasound Nakagami and entropy imaging, which are, respectively, model- and nonmodel-based backscattered statistical analysis methods for scatterer characterization. Methods: A total of 60 patients were recruited, and lymphoscintigraphy was used to score the patient’s clinical severity of each of their limb lymphedema (0: normal; 1: partial lymphatic obstruction; and 2: total lymphatic obstruction). We performed ultrasound examinations to acquire ultrasound backscattered signals for B-mode, Nakagami, and entropy imaging. The envelope amplitude, Nakagami, and entropy values, as a function of the patients’ lymphatic obstruction grades, were expressed in terms of their median and interquartile range (IQR). The values were then used in both an independent t test and a receiver operating characteristic (ROC) curve analysis. Results: For each increase in a patient’s score from 0 to 2, the envelope amplitude values were 405.44 (IQR: 238.72–488.17), 411.52 (IQR: 298.53–644.25), and 476.37 (IQR: 348.86–648.16), respectively. The Nakagami parameters were 0.16 (IQR: 0.14–0.22), 0.26 (IQR: 0.23–0.34), and 0.24 (IQR: 0.16–0.36), respectively, and the entropy values were 4.55 (IQR: 4.41–4.66), 4.86 (IQR: 4.78–4.99), and 4.87 (IQR: 4.81–4.97), respectively. The P values between the normal control and lymphedema groups obtained from B-mode and Nakagami analysis were larger than 0.05; whereas that of entropy imaging was smaller than 0.05. The areas under the ROC curve for B-mode, Nakagami, and entropy imaging were 0.64 (sensitivity: 70%; specificity: 47.5%), 0.75 (sensitivity: 70%; specificity: 75%), and 0.94 (sensitivity: 95%; specificity: 87.5%), respectively. Conclusions: The current findings demonstrated the diagnostic values of ultrasound Nakagami and entropy imaging techniques. In particular, the use of non-model-based entropy imaging enables for improved performance when characterizing limb lymphedema.

1 December 2018 in Radiology
Verified
Journal Article
Closed access
WCWen-Hui Chan
Wen-Hui Chan
YHYen-Ling Huang
Yen-Ling Huang
CLChieh Lin
Chieh Lin
CLChia-Yu Lin
Chia-Yu Lin
MCMing-Huei Cheng
Ming-Huei Cheng
SCSung-Yu Chu
Sung-Yu Chu
In participants with limb lymphedema, acoustic radiation force impulse elastography may be a useful technique to objectively assess the extent of lymphedema. PurposeTo evaluate the feasibility of cutaneous and subcutaneous limb tissue elasticity measurement in participants with limb lymphedema by using acoustic radiation force impulse (ARFI) elastography.Materials and MethodsFrom July 2015 to June 2017, ARFI elastography was performed in 64 participants with lymphedema (seven men and 57 women; age range, 23–85 years) by using a US system. Tissue stiffness quantification with shear-wave velocity (SWV) was obtained in the cutaneous and subcutaneous limb tissues. Lymphoscintigraphy was the reference standard.ResultsSWV was significantly higher in limbs with lymphatic obstruction than in unaffected limbs (cutaneous tissue: 2.75 m/sec vs 1.74 m/sec, respectively; subcutaneous tissue: 1.90 m/sec vs 1.35 m/sec, respectively; P < .001). SWV was significantly different among limbs without lymphatic drainage obstruction, with partial obstruction, and with total obstruction (cutaneous tissue: 1.74 m/sec vs 2.75 m/sec vs 2.77 m/sec; subcutaneous tissue: 1.35 m/sec vs 1.90...

26 November 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Shuen-Iu HungShuen-Iu Hung
Shuen-Iu Hung
MCMu-Tzu Chu
Mu-Tzu Chu
MHMing-Mo Hou
Ming-Mo Hou
YLYun-Shien Lee
Yun-Shien Lee
CYChan-Keng Yang
Chan-Keng Yang
CLChyong-Huey Lai
Chyong-Huey Lai
Neoantigen-reactive cytotoxic T lymphocytes play a vital role in precise cancer cell elimination. In this study, we demonstrate the effectiveness of personalized neoantigen-based T cell therapy in inducing tumor regression in two patients suffering from heavily-burdened metastatic ovarian cancer. Our approach involved the development of a robust pipeline for ex vivo expansion of neoantigen-reactive T lymphocytes. Neoantigen peptides were designed and synthesized based on the somatic mutations of the tumors and their predicted HLA binding affinities. These peptides were then presented to T lymphocytes through co-culture with neoantigen-loaded dendritic cells for ex vivo expansion. Subsequent to cell therapy, both patients exhibited significant reductions in tumor marker levels and experienced substantial tumor regression. One patient achieved repeated cancer regression through infusions of T cell products generated from newly identified neoantigens. Transcriptomic analyses revealed a remarkable increase in neoantigen-reactive cytotoxic lymphocytes in the peripheral blood of the patients following cell therapy. These cytotoxic T lymphocytes expressed polyclonal T cell receptors (TCR) against neoantigens, along with abundant cytotoxic proteins and pro-inflammatory cytokines. The efficacy of neoantigen targeting was significantly associated with the immunogenicity and TCR polyclonality. Notably, the neoantigen-specific TCR clonotypes persisted in the peripheral blood after cell therapy. Our findings indicate that personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against ovarian cancer, suggesting its promising potential in cancer immunotherapy.